BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
FRA:BSX - US1011371077 - Common Stock
92.8 EUR
+0.8 (+0.87%)
BSX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Health Care Equipment & Supplies industry. While BSX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BSX shows excellent growth, but is valued quite expensive already. These ratings would make BSX suitable for growth investing!
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
In the past year BSX had a positive cash flow from operations.
BSX had positive earnings in 4 of the past 5 years.
BSX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BSX (6.03%) is better than 73.68% of its industry peers.
BSX has a better Return On Equity (11.17%) than 71.93% of its industry peers.
BSX's Return On Invested Capital of 7.66% is fine compared to the rest of the industry. BSX outperforms 70.18% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 8.81%.
The last Return On Invested Capital (7.66%) for BSX is above the 3 year average (6.54%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
The Profit Margin of BSX (13.54%) is better than 80.70% of its industry peers.
In the last couple of years the Profit Margin of BSX has declined.
BSX has a Operating Margin of 18.69%. This is amongst the best in the industry. BSX outperforms 80.70% of its industry peers.
BSX's Operating Margin has been stable in the last couple of years.
BSX has a better Gross Margin (68.30%) than 75.44% of its industry peers.
BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
BSX has more shares outstanding than it did 1 year ago.
BSX has more shares outstanding than it did 5 years ago.
BSX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.89 indicates that BSX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.89, BSX belongs to the best of the industry, outperforming 91.23% of the companies in the same industry.
The Debt to FCF ratio of BSX is 3.33, which is a good value as it means it would take BSX, 3.33 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.33, BSX belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
BSX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
BSX has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.89 |
ROIC/WACC0.91
WACC8.4%
2.3 Liquidity
A Current Ratio of 1.37 indicates that BSX should not have too much problems paying its short term obligations.
BSX has a Current ratio (1.37) which is in line with its industry peers.
A Quick Ratio of 0.82 indicates that BSX may have some problems paying its short term obligations.
BSX has a worse Quick ratio (0.82) than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.91% over the past year.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
The Revenue has grown by 21.45% in the past year. This is a very strong growth!
BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.08% yearly.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 11.70% on average per year.
EPS Next Y20.01%
EPS Next 2Y16.91%
EPS Next 3Y15.57%
EPS Next 5Y14.08%
Revenue Next Year19.61%
Revenue Next 2Y15.21%
Revenue Next 3Y13.52%
Revenue Next 5Y11.7%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 38.19, which means the current valuation is very expensive for BSX.
BSX's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.03, BSX is valued a bit more expensive.
The Price/Forward Earnings ratio is 31.52, which means the current valuation is very expensive for BSX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
BSX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.63, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.19 | ||
| Fwd PE | 31.52 |
4.2 Price Multiples
BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. BSX is more expensive than 63.16% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as BSX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.99 | ||
| EV/EBITDA | 35.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of BSX may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 15.57% in the coming years.
PEG (NY)1.91
PEG (5Y)3.99
EPS Next 2Y16.91%
EPS Next 3Y15.57%
5. Dividend
5.1 Amount
No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (9/4/2025, 7:00:00 PM)
92.8
+0.8 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.45%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap137.51B
Analysts85
Price Target107.05 (15.36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)2.11%
PT rev (3m)1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.36%
EPS NY rev (1m)2.19%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.75%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)1.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.19 | ||
| Fwd PE | 31.52 | ||
| P/S | 8.66 | ||
| P/FCF | 45.99 | ||
| P/OCF | 37.4 | ||
| P/B | 7.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.61 |
EPS(TTM)2.43
EY2.62%
EPS(NY)2.94
Fwd EY3.17%
FCF(TTM)2.02
FCFY2.17%
OCF(TTM)2.48
OCFY2.67%
SpS10.71
BVpS12.98
TBVpS-1.69
PEG (NY)1.91
PEG (5Y)3.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.89 |
F-Score5
WACC8.4%
ROIC/WACC0.91
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y20.01%
EPS Next 2Y16.91%
EPS Next 3Y15.57%
EPS Next 5Y14.08%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.61%
Revenue Next 2Y15.21%
Revenue Next 3Y13.52%
Revenue Next 5Y11.7%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.67%
EBIT Next 3Y20.23%
EBIT Next 5Y14.94%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%